Clinical trials: Poliovirus Vaccine, Inactivated
Polio Immunity
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine.
- Trial name
- NCT07688369
- Testing
- Recombinant Poliomyelitis Vaccine (rPV), Inactivated Poliomyelitis Vaccine (IPOL)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Poliomyelitis
A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
Following licensing of PoliorixTM in Korea, this study will collect safety data about the routine use of this vaccine in 600 children according to the regulations of Korean Food and Drugs Administration (KFDA).
- Trial name
- NCT00514033
- Testing
- Poliomyelitis vaccine (inactivated) -PoliorixTM
- Where
- South Korea
- Volunteers
- 349 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccination
Immunogenicity and Safety of Sabin-IPV Replacement Vaccination
This study replaced the 2nd and 3rd dose of Salk-IPV (produced by Sanofi) with Sabin-IPV (produced by CNBG) and then reviewed the safety and immunogenicity of the vaccination, aiming to acquire scientific evidence for the…
- Trial name
- NCT04051736
- Testing
- Inactivated Polio Vaccine
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Polio, Measles
the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
This study evaluated the antibody persistence of Chinese children five years after they received four doses of sIPV, two doses of MMR vaccine and one dose of HepA-L vaccine.
- Conditions
- Polio, Measles, Rubella, Mumps
- Trial name
- NCT07338851
- Where
- 6 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pertussis, Diphtheria
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
Pediacel™ is currently licensed in the UK for use as a 3 dose regimen for the active immunisation of infants against Diphtheria, Tetanus, Pertussis, Poliomyelitis and invasive infections caused by Haemophilus influenzae type b.
- Conditions
- Pertussis, Diphtheria, Tetanus, Poliomyelitis
- Trial name
- NCT00287092
- Testing
- DT5aP-IPV-Hib 5-component Pertussis vaccine, Infanrix® -IPV+Hib
- Where
- 14 sites in Finland, Sweden
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Acellular Pertussis
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
The aims of this study are to compare the immunogenicity and safety of the GSK Biologicals' combined DTaP-IPV vaccine with separate administration of DTaP and IPV vaccines, when administered as a fifth dose of acellular pertussis…
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT00263692
- Testing
- Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
- Where
- 15 sites in United States
- Volunteers
- 401 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Polio
Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan
The aim of the study is to assess the immunogenicity of SP059 (IMOVAX POLIO®: Inactive Poliovirus Vaccine) vaccine against poliovirus and safety after fifth dose.
- Trial name
- NCT02005536
- Testing
- IMOVAX POLIO®: Inactive Poliovirus Vaccine
- Where
- 4 sites in Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Poliomyelitis, Vaccine Reaction
Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
Eupolio is inactivated poliovirus vaccine (IPV). Major purpose of this study is to evaluate safety of Eupolio in 2,000 infants. In addition to the safety, long-term protection after completion of the three primary vaccinations…
- Trial name
- NCT05431933
- Testing
- Eupolio
- Where
- 10 sites in Philippines, Thailand
- Volunteers
- 2,001 people, healthy volunteers welcome
- Sponsor
- LG Chem
Diphtheria, Tetanus
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia
The purpose of this study is to evaluate the immune response, safety and reactogenicity after receiving combined DTPa-IPV/Hib vaccine when administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age and…
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT02858440
- Testing
- Infanrix-IPV/Hib
- Where
- 5 sites in Russia
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster in children ≥ 4 to < 7 years of age in the US and Puerto Rico who were previously vaccinated with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Measles
- Trial name
- NCT01346293
- Testing
- Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus, Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 3,372 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rotavirus
Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants
The purpose of this study is to evaluate the immunogenicity and safety of the diphtheria, tetanus, pertussis and inactivated poliovirus (DPT-IPV) vaccine Squarekids administered with or without the GSK Biologicals' liquid Rotarix…
- Trial name
- NCT02907216
- Testing
- Squarekids, Rotarix
- Where
- 11 sites in Japan
- Volunteers
- 292 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rotavirus Disease
Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)
The study will evaluate the immunogenicity of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) with concomitant administration of RotaTeq™ (V260) in healthy Japanese infants.
- Trial name
- NCT01926015
- Testing
- RotaTeq™ (V260), DTP-IPV
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Meninigitis, Serogroup C
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant…
- Trial name
- NCT00161941
- Where
- 11 sites in Austria, Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diphtheria, Tetanus
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Venus (NCT02458183)
- Testing
- DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine
- Where
- 20 sites in South Korea, Thailand
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Pertussis, Tetanus
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis
Primary objective: To determine the safety and immunogenicity of tetanus and diphtheria toxoids adsorbed combined with component pertussis and inactivated poliomyelitis vaccine grown on vero cells (TdcP-IPV) compared to tetanus…
- Conditions
- Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT02040636
- Testing
- Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV, Hepatitis B vaccine
- Where
- Canada
- Volunteers
- 277 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diphtheria, Tetanus
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants
The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT04073459
- Testing
- DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV
- Volunteers
- 336 people, healthy volunteers welcome
- Sponsor
- LG Chem
Poliomyelitis
Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
The purpose of this study is to evaluate the safety of sIPVs of different dosages in adults, children and infants in a phase I open-label study, and then assess its immunogenicity and safety in healthy infants between 60 and 90…
- Trial name
- NCT02985320
- Testing
- Single-dose regimen of high dosage investigational sIPV, Single-dose regimen of medium dosage investigational sIPV, Three-dose regimen of high dosage investigational sIPV
- Where
- China
- Volunteers
- 708 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Poliomyelitis
Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)
The study aimed to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine in infants aged two months (60~89 days).
- Trial name
- NCT07297186
- Testing
- sIPV, wIPV
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Poliomyelitis
Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
This Phase III study has been designed to compare the SII Inactivated Salk Polio Vaccine (Adsorbed) with Sii licensed IPV by testing the vaccine in infants (three doses administered 4 weeks apart, starting at 6-8 weeks of age) in…
- Trial name
- NCT05163561
- Testing
- SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot A, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot B, SII Inactivated Salk Polio Vaccine (Adsorbed) - Lot C
- Where
- Bangladesh
- Volunteers
- 1,072 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Poliomyelitis
Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization
This study is a supplementary study of an already finished randomised, double-blinded, and placebo controlled phase 2 clinical trial of an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd.…
- Trial name
- NCT04618783
- Testing
- Three doses of low-dosage investigational sIPV, vaccinated within one-month interval between doses, Three doses of medium-dosage investigational sIPV, vaccinated within one-month interval between doses, Three doses of high-dosage investigational sIPV, vaccinated within one-month interval between doses
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd